


In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please cancel claims 12, 14, and 16 without prejudice to their presentation in another application, amend claims 1-5, 7, 9, 10, 13, 15, and 17-20, and add new claim 21 as follows.

1. (currently amended) A compound of formula I



wherein

R^1 represents a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a C_{1-4} alkyl group optionally substituted by one or more fluoro, halo, cyano, a group $OSO_2C_{1-4}alkyl$ wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a $C_{1-4}alkyl$ group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a $C_{1-4}alkyl$ group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ~~ring~~, ring;

n represents 0, 1, 2 or 3;

R^2 represents a $C_{1-4}alkyl$ group optionally substituted by one or more fluoro or a $C_{1-4}alkoxy$ group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a $C_{1-4}alkyl$ group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a $C_{1-4}alkyl$ group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(CH_2)_pC_{3-10}$ cycloalkyl $(CH_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4 , respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group $-N(R^3)-L^1-$ or the group $L^1-N(R^4)$ together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively;

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro;

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: fluoro or C_{1-4} alkyl; or L^2 may also represent a 5-6 membered carbocyclic ring fused to R^5 , to R^5 ;

R^5 represents phenyl or naphthyl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinoliny, indolyl, benzofuranyl, benzo[b]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-a]pyridinyl, 5H-pyrrolo[2,3-b]pyrazinyl, 1H-pyrrolo[3,2-c]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-indazolyl, 1H-pyrrolo[3,2-h]quinoliny, 1H-pyrrolo[3,2-b]pyridinyl, 2,1,3-benzothiadiazolyl, 2,1,3-benzoxadiazolyl, quinazolinyl or triazolyl wherein each R^5 is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $S(O)_aR^y$ in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, or by a group $O_z(CH_2)_wR^z$ in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, or a C_{1-4} alkoxy group optionally substituted by one or more fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with the proviso that when

R^1 represents a C_{1-4} alkoxy group optionally substituted by one or more fluoro or a C_{1-4} alkyl group optionally substituted by one or more fluoro; and

n represents 0 or 1; and

R^2 represents a C_{1-4} alkyl group optionally substituted by one or more fluoro or a C_{1-4} alkoxy group optionally substituted by one or more fluoro; and

m represents 0 or 1; and

R^3 represents H or a C_{1-4} alkyl group; and

L^1 represents a cyclohexyl group wherein the two nitrogens bearing R^3 and R^4 , respectively, are linked to the cyclohexyl group either via the 1,3 or the 1,4 positions of the cyclohexyl group or L^1 represents a cyclopentyl group wherein the two nitrogens bearing R^3 and R^4 , respectively, are linked to the cyclopentyl group via the 1,3 position of the cyclopentyl group; and

L^2 represents an alkylene chain $(CH_2)_s$ in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C_{1-4} alkyl group; and

R^5 represents aryl wherein aryl means phenyl or naphthyl each of which is optionally substituted by one or more of the following: halo, a C_{1-4} alkyl group or phenyl, or

R^5 represents a heterocyclic group wherein the term heterocyclic group means thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl or benzo[*b*]thienyl each of which is optionally substituted by one or more of the following: halo or a C_{1-4} alkyl group;


or L^2 represents a C_{5-6} cycloalkyl group which is fused to an R^5 which is phenyl or a heteroaryl group selected from thienyl, furyl or pyrrolyl;

then R^4 does not represent H or a C_{1-4} alkyl group; and excluding 1,4-anhydro-2,3,5-trideoxy-3-[(3,4-dichlorophenyl)methyl]amino]-5-[(4-ethoxy-2-quinolinyl)amino]-D-erythro-pentitol amino]-D-erythro-pentitol.

2. (currently amended) A compound as claimed in ~~claim 1~~ claim 1 in which L^1 represents a monocyclic $-(CH_2)_pC_{5-6}(CH_2)_q-$ cycloalkyl group in which p and q are independently 0 or 1 wherein there are 3 carbon atoms between the two nitrogens bearing R^3 and R^4 , respectively, wherein one of the carbons of the cycloalkyl group may be replaced by O or the group $-N(R^3)-L^1-$, or the group $L^1-N(R^4)$, together represent a saturated heterocyclic ring containing from 4 to

6 carbon atoms and the nitrogen bearing R^3 or R^4 respectively.

3. (currently amended) A compound ~~according to claim 1 or claim 2~~ of formula IA



in which

R^1 represents chloro, fluoro, methoxy or a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl ~~group~~ group;

n represents 0, 1 or 2 and when $n=1$ the substituent is attached to either position 6 or 7;

R^2 represents a C_{1-4} alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H;

A represents CH_2 and t is 0 or 1;

R^4 represents H;


L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R^5 represents aryl or a heterocyclic group selected from thienyl, furyl, pyridyl, pyrrolyl, quinolinyl, indolyl, benzofuranyl, benzo[*b*]thienyl, imidazolyl, benzimidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyrazolyl, oxazolyl, imidazo[1,2-*a*]pyridine, 5*H*-pyrrolo[2,3-*b*]pyrazine, 1*H*-pyrrolo[3,2-*c*]pyridine, 1*H*-pyrrolo[2,3-*c*]pyridine, 1*H*-pyrrolo[2,3-*b*]pyridine, 1*H*-indazole each of which is optionally substituted by one or more of the following: cyano,

halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or by a group S(O)_aR^y in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, or by a group O_z(CH₂)_wR^z in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄alkoxy group optionally substituted by one or more ~~fluoro~~ fluoro;

as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts thereof.

4. (currently amended) A compound ~~according to any previous claim~~ of formula IB



in which

R¹ represents H, methoxy, dimethylamino, chloro or fluoro;

R² represents H, a C₁₋₄alkyl group or a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R³ represents H;


A represents CH₂ and t is 0 or 1;

R⁴ represents H;

L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R^5 represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl, pyrazolyl, or quinolin-2-yl each of which is optionally substituted by one or more of the following: cyano, halo, a C_{1-4} alkyl group optionally substituted by one or more fluoro, a C_{1-4} alkoxy group optionally substituted by one or more fluoro and in addition when R^5 is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C_{1-4} alkyl group optionally substituted by one or more fluoro and when R^5 is indol-3-yl it is optionally additionally substituted by 1-(thiazol-5-yl)methyl which is optionally substituted by halo.

5. (currently amended) A compound ~~according to any previous claim~~ of formula IC



in which

R^1 represents H, methoxy, dimethylamino, chloro or fluoro;

R^2 represents H, a C_{1-4} alkyl group or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group $CONR^cR^d$ in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

R^3 represents H;

A represents CH_2 and t is 0 or 1;

R^4 represents H;

L^2 represents CH_2 , $C(CH_3)_2$ or CF_2 ; and

R⁵ represents 2-thienyl, 3-thienyl, indol-3-yl, 2-pyrrolyl, 5-pyrimidinyl, 4-thiadiazolyl, pyrazolyl, 1*H*-pyrrolo[3,2-*b*]pyridinyl or quinolin-2-yl each of which is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro and in addition when R⁵ is 2-thienyl it is optionally additionally substituted by pyridyl, 2-thienyl or 3-pyrazolyl each of which is optionally substituted by halo or a C₁₋₄ alkyl group optionally substituted by one or more fluoro and when R⁵ is indol-3-yl it is optionally additionally substituted by 1-(thiazol-5-yl)methyl which is optionally substituted by halo.

6. (original) A compound as claimed in any one of claims 1 to 5 in which p is 0, q is 0 and L¹ is 1,3-cyclohexyl.

7. (currently amended) A compound as claimed in any ~~previous claim~~ one of claims 1 to 5 in which the two nitrogen atoms are in a trans orientation on the cycloalkyl ring.

8. (original) A compound as claimed in claim 7 wherein the absolute configuration of the cycloalkyl carbon atoms to which the nitrogen atoms are attached is S, S.

9. (currently amended) A compound according to any ~~previous claim~~ one of claims 1 to 5 in which R⁵ represents one of the following:

1*H*-pyrrolo[3,2-*c*]pyridinyl;
1*H*-pyrrolo[2,3-*b*]pyridinyl;
1*H*-indazolyl;
1-imidazo[1,2-*a*]pyridinyl;
5*H*-pyrrolo[2,3-*b*]pyrazinyl;
1*H*-pyrrolo[3,2-*b*]pyridinyl;
1*H*-pyrrolo[3,2-*h*]quinolinyl;
2,1,3-benzothiadiazolyl; and
2,1,3-benzoxadiazolyl;

wherein each of these heterocycles is optionally substituted by one or more of the following:

cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, or by a group S(O)_aR^y in which a is 0, 1 or 2 and R^y is phenyl optionally substituted by cyano, halo, a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, or by a group O_z(CH₂)_wR^z in which z and w independently are 0 or 1 and R^z represents phenyl or a heterocyclic group selected from thienyl, pyridyl, thiazolyl, pyrazolyl, wherein each R^z is optionally substituted by one or more of the following: cyano, halo, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, or a C₁₋₄alkoxy group optionally substituted by one or more fluoro.

10. (currently amended) A compound as claimed in any ~~previous claim~~ one of claims 1 to 5 in which L¹ represents a (CH₂)_pC₃₋₁₀ cycloalkyl(CH₂)_q group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R³ and R⁴, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group -N(R³) -L¹- or the group L¹-N(R⁴) together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R³ or R⁴ respectively; with the proviso that L¹ is not 1,4-cyclohexyl or 1,3-cyclopentyl.

11. (original) One or more of the following compounds:

N,N-dimethyl-2-[(3-{[(5-pyridin-2-yl-2-thienyl)methyl]amino}cyclohexyl)amino]-quinoline-4-carboxamide;

(1*S*,3*S*)-*N*-(6-chloro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-3-yl)methyl]cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*R*,3*R*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methoxyquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-3-

yl)methyl]cyclopentane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-(3-thienylmethyl)cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrol-2-yl)methyl]cyclohexane-1,3-diamine;

N-(6-chloroquinolin-2-yl)-*N'*-(quinolin-3-ylmethyl)cyclohexane-1,3-diamine;

*N*⁶,*N*⁶-dimethyl-*N*²-{3-[(3-thienylmethyl)amino]cyclohexyl}quinoline-2,6-diamine;

(1*S*,3*S*)-*N*-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-*N'*-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(1,2,3-thiadiazol-4-ylmethyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-[(5-pyridin-2-yl-2-thienyl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-({1-[(2-chloro-1,3-thiazol-5-yl)methyl]-1*H*-indol-3-yl}methyl)-*N'*-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-({5-[1-methyl-5-(trifluoromethyl)-1*H*-pyrazol-3-yl]-2-thienyl}methyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(2,2'-bithien-5-ylmethyl)-*N'*-(6-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

*N*⁴,*N*⁴-dimethyl-*N*²-{3-[(3-thienylmethyl)amino]cyclohexyl}quinoline-2,4-diamine;

*N*⁴,*N*⁴-dimethyl-*N*²-[3-({2-(phenylsulfonyl)-1,3-thiazol-5-yl}methyl)amino]cyclohexyl]quinoline-2,4-diamine;

*N*²-(3-[(2,4-dimethoxypyrimidin-5-yl)methyl]amino)cyclohexyl)-*N*⁴,*N*⁴-dimethylquinoline-2,4-diamine;

3-(6-methoxy-4-methylquinolin-2-yl)-*N*-methyl-*N*-(3-thienylmethyl)-3-azabicyclo[3.2.1]octan-8-amine;

6-methoxy-4-methyl-*N*-[(((1*R*,2*S*)-2-[(1-methyl-1*H*-indol-3-yl)methyl]amino)cyclopentyl)methyl]quinolin-2-amine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-3-[(3-[(7-methoxy-4-methylquinolin-2-yl)amino]cyclopentyl)amino)methyl]-

1-methyl-1*H*-indole-6-carbonitrile;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-2-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-({ 1-[3-(trifluoromethyl)pyridin-2-yl]-1*H*-indol-3-yl}methyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indazol-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-({ 1-[4-(trifluoromethyl)phenyl]-1*H*-pyrrol-3-yl}methyl)cyclopentane-1,3-diamine;

3-[(1*S*,3*S*)-3-[(7-methoxy-4-methylquinolin-2-yl)amino]cyclopentyl]amino)methyl]-1-methyl-1*H*-indole-5-carbonitrile;

(1*S*,3*S*)-*N*-{[5-difluoromethoxy-1*H*-indol-3-yl]methyl}-*N'*-(7-methoxy-4-methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1*S*,2*S*,4*R*,6*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

(1*R*,2*S*,4*S*,6*S*)-*N*-(6-methoxy-4-methylquinolin-2-yl)-*N'*-(3-thienylmethyl)bicyclo[2.2.1]heptane-2,6-diamine;

(1*S*,2*S*,4*R*,6*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-indol-3-yl)methyl]bicyclo[2.2.1]heptane-2,6-diamine;

6-methoxy-4-methyl-*N*-[(1*S*,2*R*)-2-({ (1-methyl-1*H*-indol-3-yl)methyl}amino)methyl]cyclopentyl]quinolin-2-amine;

(1*S*,3*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[3,2-*h*]quinolin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[2,3-*c*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(7-methoxy-4-methylquinolin-2-yl)-*N'*-[(1-methyl-1*H*-pyrrolo[3,2-*b*]pyridin-3-yl)methyl]cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-(6-fluoro-4-methylquinolin-2-yl)-*N'*-(imidazo[1,2-*a*]pyridin-3-ylmethyl)cyclopentane-1,3-diamine;

(1*S*,3*S*)-*N*-{[5-(Benzyloxy)-1-methyl-1*H*-indol-3-yl]methyl}-*N'*-(7-methoxy-4-

methylquinolin-2-yl)cyclopentane-1,3-diamine;

(1S,3S)-N-(7-Methoxy-4-methylquinolin-2-yl)-N'-[3-(trifluoromethoxy)benzyl]-cyclohexane-1,3-diamine;

(1S,3S)-N-(2,1,3-Benzothiadiazol-4-ylmethyl)-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

(1S,3S)-N-[(1,3-Dimethyl-1H-pyrazol-4-yl)methyl]-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine; and

(1S,3S)-N-(2-Bromo-4-methoxybenzyl)-N'-(7-methoxy-4-methylquinolin-2-yl)cyclohexane-1,3-diamine;

and pharmaceutically acceptable salts thereof.

12. (canceled).


13. (currently amended) A pharmaceutical formulation comprising a compound of formula ~~I~~, as defined in any one of claims 1 to 5 or claim 11 and a pharmaceutically acceptable adjuvant, diluent or carrier.

14. (cancelled).


15. (currently amended) A method of treating obesity, a psychiatric disorder ~~psychiatric disorders~~, anxiety, an anxio-depressive disorder ~~anxio-depressive disorders~~, depression, bipolar disorder, ADHD, a cognitive disorder ~~cognitive disorders~~, a memory disorder ~~memory disorders~~, schizophrenia, epilepsy, ~~and related conditions~~, and a neurological disorder ~~neurological disorders~~ and a pain related disorder ~~pain-related disorders~~, comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.

16. (canceled).

17. (currently amended) A process for the preparation of a compound ~~compounds~~ of formula I



comprising reacting a compound of formula II



in which ~~R¹, R², R³, R⁴, L¹, n and m are as previously defined~~

R¹ represents a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO₂C₁₋₄alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R² represents a C₁₋₄alkyl group optionally substituted by one or more fluoro or a C₁₋₄alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄ alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C₁₋₄alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;


m represents 0 or 1;

R³ represents H or a C₁₋₄ alkyl group;

L¹ represents a (CH₂)_pC₃₋₁₀ cycloalkyl(CH₂)_q group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R³ and R⁴, respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group -N(R³) -L¹ - or the group L¹-N(R⁴) together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R³ or R⁴ respectively; and

R⁴ represents H or a C₁₋₄ alkyl group optionally substituted by one or more of the following: fluoro or C₁₋₄ alkoxy optionally substituted by one or more fluoro;


with a compound of formula III



III

in which R⁵ is as previously defined and L² represents a group which after reaction of compounds II and III gives L² on reduction, under reductive alkylation conditions.

18. (currently amended) A compound ~~Intermediates~~ of formula II



II

in which ~~R¹, R², R³, R⁴, L¹, n and m are as defined in claim 1~~

R¹ represents a C₁₋₄ alkoxy group optionally substituted by one or more fluoro, a C₁₋₄ alkyl group optionally substituted by one or more fluoro, halo, cyano, a group OSO₂C₁₋₄alkyl wherein the alkyl group is optionally substituted with one or more fluorine atoms, a group NR^aR^b in which R^a and R^b independently represent H or a C₁₋₄alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring

optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

n represents 0, 1, 2 or 3;

R^2 represents a C_{1-4} alkyl group optionally substituted by one or more fluoro or a C_{1-4} alkoxy group optionally substituted by one or more fluoro, a group NR^aR^b in which R^a and R^b independently represent H or a C_{1-4} alkyl group or R^a and R^b together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring optionally including an O, a group CONR^cR^d in which R^c and R^d independently represent H or a C_{1-4} alkyl group or R^c and R^d together with the nitrogen atom to which they are attached represent a saturated 3 to 7 membered heterocyclic ring;

m represents 0 or 1;

R^3 represents H or a C_{1-4} alkyl group;

L^1 represents a $(\text{CH}_2)_p\text{C}_{3-10}\text{cycloalkyl}(\text{CH}_2)_q$ group in which p and q are independently selected from 0 and 1 and in which the cycloalkyl group may be monocyclic or bicyclic and optionally may be bridged provided that the two nitrogens bearing R^3 and R^4 , respectively, are not linked to the same carbon atom, and wherein one of the carbons may be replaced by O or, alternatively, the group $-\text{N}(\text{R}^3)-\text{L}^1-$ or the group $\text{L}^1-\text{N}(\text{R}^4)$ together represent a saturated bicyclic heterocyclic ring containing from 2 to 9 carbon atoms and the nitrogen bearing R^3 or R^4 respectively; and

R^4 represents H or a C_{1-4} alkyl group optionally substituted by one or more of the following: fluoro or C_{1-4} alkoxy optionally substituted by one or more fluoro.

19. (currently amended) A compound ~~of formula V~~ selected from one or more of:
 (1S, 3S)-Dibenzyl-cyclohexane-1,3-diylbiscarbamate; and
 (1S, 3S)-Cyclohexane-1,3-diamine dihydrochloride.
20. (currently amended) A method of treating obesity, type II diabetes, or Metabolic syndrome ~~and prevention of type II diabetes~~ comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient

in need thereof.

21. (new) A method of preventing type II diabetes comprising administering a pharmacologically effective amount of a compound as claimed in any one of claims 1 to 5 or claim 11 to a patient in need thereof.